Benzinga | Feb 17, 2021 07:10AM EST

AC Immune To Highlight Alzheimer's Vaccine At SVB Leerink 10th Annual Global Healthcare Conference Feb. 24, 11:2011:50 am ET

SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 22--26, 2021.



During a fireside chat, AC Immune CEO Prof. Andrea Pfeifer will discuss the Company's execution strategy to advance and accelerate its precision medicine approach to targeting neurodegenerative diseases. Prof. Pfeifer will also highlight AC Immune's novel anti-phospho-Tau (pTau) vaccine candidate ACI-35.030, including recent interim Phase 1b/2a results that showed promising immunogenicity and safety in patients with early Alzheimer's disease. AC Immune is developing ACI-35.030 in collaboration with its strategic partner Janssen Pharmaceuticals, Inc.

SVB Leerink 10th Annual Global Healthcare Conference

Date: February 24, 2020 | 11:20--11:50 am ET / 5:20--5:50 pm CET

Format: Fireside chat

Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

A webcast of the fireside chat will be available on the Events Page of AC Immune's website.